Member Info for Vascular

Published Today.

“ The new capability, which went live on 14 July 2025, allows clinicians in hospitals, GP practices and community settings to view a patient’s full list of radiology images within the GM Care Record, powered by Graphnet Health.”

“ This capability will also support our neighbourhood teams – including GPs, community services and urgent care professionals – by giving them access to vital information without needing to wait for hospital systems or paper records.

“That’s exactly the kind of innovation that will help make the Neighbourhood Health Service a reality.”

“ By further integrating essential clinical data and eliminating the need to switch between systems to access imaging, the new capability is expected to benefit hospital specialists, neighbourhood care teams and primary care clinicians, reinforcing a more connected, patient-centred model of care.

“This is expected to lead to faster turnaround times, potentially reducing diagnostic delays; streamlined workflows owing to one-click access to images via the GM Care Record; improved continuity of care across community and hospital services; and richer clinical context by allowing images to be viewed alongside other patient data.

A second phase, which will allow access to detailed radiology reports and metadata within the GM Care Record, is planned for later this year.”

GL Vas

https://www.digitalhealth.net/2025/07/radiology-images-now-accessible-through-gm-care-record/

Panmure Liberum to upgrade its price target to 32p from 24p.

"The SCOPE trial data also revealed strong progression-free survival (PFS) outcomes, a crucial measure indicating how long patients survive without their disease worsening, of up to 22 months.

This far exceeds the standard of care's 7.9 months. The disease control rate (DCR), measuring the percentage of patients whose cancer did not progress, reached an impressive 88% compared to the standard 58%.

Moreover, Scancell's vaccine is unique in being the only off-the-shelf DNA-based vaccine nearing late-stage development for melanoma.

This potentially offers faster, more cost-effective treatment than personalised alternatives under investigation by industry peers."

https://www.proactiveinvestors.com/companies/news/1075191/scancell-broker-raises-price-target-after-impressive-cancer-vaccine-results-1075191.html

Sorry. This is the most recent copy , deadline for submission delayed to 11th August 25.

https://www.find-tender.service.gov.uk/Notice/035205-2025

https://www.find-tender.service.gov.uk/Notice/035205-2025

You’re welcome Barnacle. Here is another Framework related to “Community Diagnostics” Do you think FDBK meet the criteria. Is it relevant. Hard to know. Award decision date (estimated) 28th July 2025.GL Vas

https://www.find-tender.service.gov.uk/Notice/020811-2025

AXREM, the UK trade association representing the medical imaging, radiotherapy, healthcare IT and care innovation industry.

https://www.axrem.org.uk/axrem-statement-supporting-the-governments-vision-for-community-based-diagnostics-in-the-10-year-plan/

More info here from when call out for interested digital company’s in Feb , this year.

https://d3tenders.com/contract/?ocid=ocds-b5fd17-198f49ca-b5b1-4175-84b5-02c4788308d5

This ( new) framework starts on 1 August 2025, runs for 24 months and ends on 31 July 2027. There is an option to extend for an additional 24 months.

This replaces the former Medical IT Departmental Software and Hardware Solutions framework.

Feedback Medical are listed as one of the 54 suppliers.

This is a direct framework agreement. To order products:

https://www.supplychain.nhs.uk/product-information/contract-launch-brief/digital-diagnostic-solutions/#

Re: the NHS-led Cancer Vaccine Launchpad (CVLP). Is it just pure coincidence that Scancell has been selected to become the second biopharma company – after BioNTech – to join a UK government program designed to accelerate research into personalized cancer vaccines! What are the odds on that …..

Thanks JJJJJ,

Thanks for your reply.

Yes, it really is an investment based on gut feeling for me at present. Even though I have been in and out over the years ….i cant help thinking that this is now FDBKs time.

Even the recent Update ( last week) from Sir James Mackey, CEO, NHS England on the 10 year NHS plan stated that

“ At the heart of this transformation is the reimagining of outpatient care, which will be critical to delivering the shifts outlined in the plan. We will move decisively toward straight-to-test pathways, reducing unnecessary appointments and accelerating diagnosis. This will be complemented by the expansion of one-stop services, enabling patients to receive consultation, testing, and treatment in a single visit—minimising delays and improving experience.

Technology will be a key enabler. From AI-supported triage to interoperable patient records, we will harness tech-enabled solutions to streamline care and empower patients. The NHS App will evolve into a true digital front door, offering more convenient access to services, results, and personalised health information.

A new model of working across primary and secondary care will underpin these changes. Integrated neighbourhood teams will collaborate across boundaries, supported by shared data and aligned incentives. This will ensure patients receive the right care, in the right place, at the right time. We will join up care for patients with multiple long-term conditions.”

As we know this is something that FDBK , not only have the solution , which has been tested, piloted in the NHS but also has won awards …so as a technological solution it must have a good profile within the NHS….

Even with some moderate success the £8 m revenues looks very achievable , and could be surpassed…..what is needed now is some hard evidence from FDBK that they are in business in the UK! This share will fly on a descent contract IMO , the risk of course is that I have read this wrong , and nocontract , no business .

Lot of money entering this space from the looks of it. Gl vas

A bit of a long, read this ....

Developed in partnership between London’s five integrated care boards, NHS England London Region, and the wider London Health and Care Partnership (London Councils, Greater London Authority, UK Health Security Agency, and the Office for Health Improvement and Disparities in London), with support from London wide Local Medical Committees. May 2025

The thing that stood out for me was that one of their key priority objectives is..

" Modelling the impact of the shift to neighbourhood working across London’s current provider landscape. This includes key priorities such as reviewing the Outpatient model in London.".

hrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2025/05/A-Neighbourhood-Health-Service-for-London-TOM-Final.pdf

Quote from FDBK on the recent INNOVATORS ACCELARATOR NETWORK

"By digitising patient pathways and enabling asynchronous multi-disciplinary team working Bleepa® can improve productivity in the NHS with existing clinical resources, reduce patient wait times by up to 63% and reduce unnecessary first and follow up outpatient appointments by up to 90%"

Up to 90% reduction, cant improve on this much more unless they stop doing outpatient appointments all together !

Entry year 2025

Innovation type: Transformational

https://nhsaccelerator.com/innovations/bleepa/#:~:text=By%20digitising%20patient%20pathways%20and%20enabling%20asynchronous%20multi-disciplinary,follow%20up%20outpatient%20appointments%20by%20up%20to%2090%25.

Anyone take a guess what the sp could look like if FDBK achieve the first trigger for options of £8 million revenue ?

Thanks for your thoughts Emptyend.

Yes, it makes sense what you and others are saying. However, I can't help thinking that as its not a double blind trial ( I'm no expert here, as you can tell :) ) and new info/ status reports / test results of all patients on trial etc could be / coming on stream daily about each patients progress etc. Then as long as its allowed and legal - then i would expect with such an important trial that Scancell would ask for updates daily, or close, showing more granular data from each of the trial sites, not just general comments.

i would want to know the status of each of the patients in the trial on a very regular basis, because as you say they need to know about any aberrations fast or any new developments regardless of whether positive or negative so they can build this into their planning and narrative going forward....of course even neutral feedback is just as informative , trial continuing as expected / hoped.

Anyway, thanks again. Cant help thinking that the initial data being used regularly at present on social media is not only a reminder / raising awareness but is a green light that the trial data continues to look good. Anyway, everything will become more clear, and certain in a week or so.

Many thanks for all your replies and opinions.

Re: Chester’s post . The clinical lead should be close to providing Scancell with the very latest data sometime very soon, if it’s to be made available to investors in next few weeks or so.

Meanwhile , it does seem that we are agree that Scancell most probably know the direction of travel and feel confident to continue ( just a few weeks ago) to present initial trial data, with a very high probability that they already know this initial data is still on track and remains valid, at least. Thanks again .vas

This v. positive info , the Initial Data pasted below from RNS just over a few weeks ago !! (Cohort 4, 26th June 25) , although very positive, it is old data, the initial data.

However, the fact they have purposely used this positive data again, a few weeks ago is interesting, especially in the light of what info, the BODs had access to when they wrote and published this RNS.

Have the BODs had access to new data since the older initial data? if so they were happy to continue using the excellent older data, as if it had not materially change OR were they blind to any further new data and so repeated the initial data - as its would be the only data they have available.

I know we are expecting a release of new data, anytime soonish, and that will be the official update -so i understand that there is a time an place to update the public on new data - but its all about what they were aware of in June, when they wrote the RNS . They surely would not repeat the data, knowing full well there has been a negative aberration, would they?

"SCOPE (NCT04079166) is a Phase 2, multi-centre open-label study, investigating SCIB1/iSCIB1+, with checkpoint inhibitors (CPIs) in late-stage melanoma and will enroll 140+ patients across four cohorts. Initial data from 25 patients in Cohort 1, receiving first-generation SCIB1 ImmunoBody® in combination with checkpoint inhibitors, ipilimumab and nivolumab, showed 84% disease control rate, 80% progression free survival (PFS), with a 20% complete response (CR) rate, and 72% ORR, demonstrating a significant improvement over standard of care treatment."

Sorry to bang on about this but how much is reasonable for the BODS of a company to know about the progression of the trials ( assuming the trial is not a blind trial, so info is much more available such as this trial) GL all Vas

A couple of questions based on common sense assumptions here...please forgive me if they appear amateurish - please put me straight if these assumptions are inaccurate.

1) If I were on the BODs, I imagine i would be privy to far more trial result data than anyone else on the planet , and would be updated immediately as the trial progresses and as it becomes available .....so my question is would they be updated daily /weekly or maybe monthly on the new data as it lands? Do they know as much as anyone else involved in these trials or will there be a big reveal to the BODs at a later stage ( are they blind to new data and results until a future date) .

2) IF the BODs have a constant update on data / progress of trials - then why would they keep publicising the potential for good outcomes on social media knowing that the data does not support these potentially positive outcomes. my question is how much would you expect the company BODS to know regarding the very latest trial data and how often would they( and how often) would they be updated.

What I'm trying to find out is whether the BODS of Scancell are "presently" as blind to data outcomes from trial as we are !

If they are privy to direction of travel in most recent trial updates, and continue to promote the possibility of good results then surely , this bodes well for the a positive outcome for many of the patients in trial, the company and its investors.

Many thanks in advance and good luck Scancell and ALL.

Jimbo. If the horse is dead as you seem to then you have already lost your money here, its down to you to handle that ! Don't take it out on those who think FDBK still have a chance to turn this share price around. We all know the risks, and don't need to be protected .......as neither of us can tell the future .....I prefer to believe that the past has novrefkection on the future posabilitys here....especially with this new ten year plan, the ink still wet, and everything to play for ..... this sp can reverse very fast when the time comes .....I'm more analogue than AI, actually!

Yes, would do no harm in an update, even one with a nod and a wink of possible, possibilities !!

Even though hopefully FDBK are involved / will be in the ten year plan in some way, I don't suppose there is anything concrete at present that can be announced until a contract or MOU is agreed - so whatever else they put out will only be similar to what is presently put out on social media, i guess.

i must say FDBK get several major ticks in aligning with the four principles of the closer neighbourhood care / new health neighbourhood centres etc in the ten year plan.

Out of the four main bullet points , FDBKs communication solution fits them all .....

* Prime Minister launches government’s 10 Year Health Plan to bring the NHS closer to home

* Neighbourhood health services to be rolled out across the country, bringing diagnostics, mental health, post-op, rehab and nursing to people’s doorsteps.

* Neighbourhood health centres will house services under one roof, open at evenings and weekends

* Plan for Change will rebuild the NHS to train thousands more family doctors, transform hospital outpatient appointments and provide personalised care plans for complex needs

It is the " transform hospital outpatient appointments" bulletin point which stands out for me, as this is what FDBK have been banging on about most recently and how the FDBK solution cuts out something like 80% / 90% of physical outpatient appointments ( and the hospital doctors time) with the patient going from GP , straight into testing/ scan etc and then referral to consultant for discussion once a diagnosis made or for many treated at home / in community when appropriate.

All the above will require a joined up method of communication between primary and secondary care services where everyone involved in someones care can access the same info, read from the same page and in real time.

https://www.gov.uk/government/news/pm-launches-new-era-for-nhs-with-easier-care-in-neighbourhoods

You can buy via IG.

Earlier this year INC were chosen as one of their twelve shares for 2025. INCs mid year appraisal at 47.30 mins and at 4p, they are still very bullish.

https://podcasts.apple.com/gb/podcast/12-for-2025-companies-on-our-radar-review-pow-gmet/id1593750832?i=1000715710756

This article from April 25 talks about FDBKs cash position, among other things.

https://joshthompson.co.uk/investing/feedback-plc-nhs-restructuring-strategic-adjustments-revenue-dip/